Loading stock data…
ARDX
$6.61-0.17 (-2.51%)
Market ClosedLast close May 11
Ardelyx, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ardelyx, Inc. in the Healthcare sector is trading at $6.61. The stock is currently 21% below its 52-week high of $8.40, remaining 9.3% above its 200-day moving average. Technical signals show neutral RSI of 65 and bullish MACD crossover, explaining why ARDX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 65) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.61
Potential Upside
5%
Whystock Fair Value$6.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$16.33+147.1%
Range$13.00 – $19.00
Fundamentals
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritabl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.77%
Volume
Today's trading volume
4.04M
Recent News
Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's Changed
In early May 2026, Ardelyx presented a new long-term analysis at the National Kidney Foundation meetings showing that XPHOZAH (tenapanor) reduced serum phosphate in chronic kidney disease patients on dialysis without clinically meaningful changes in other electrolytes, nutrition markers, body mass, or blood pressure, reinforcing its safety profile as an add-on therapy. The extended NORMALIZE and OPTIMIZE data, together with Ardelyx’s peer exchange on XPHOZAH’s first-in-class mechanism,...
Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance
Ardelyx (ARDX) reported first quarter 2026 results, with revenue of US$94.47 million and a net loss of US$37.61 million, and reiterated full-year revenue guidance for IBSRELA and XPHOZAH. See our latest analysis for Ardelyx. Ardelyx’s latest earnings release and guidance update come after a strong 1 year total shareholder return of 91.89%, while the 30 day share price return of 18.93% suggests momentum has picked up again around US$7.10. If this earnings driven move has you looking beyond...
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report
It's been a pretty great week for Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders, with its shares surging 16% to US$6.88 in...
Ardelyx Inc (ARDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments
Ardelyx Inc (ARDX) reports significant revenue increases for IBSRELA and XPHOZAH, while navigating operational challenges and investing in future growth.
Ardelyx, Inc. Q1 2026 Earnings Call Summary
Moby summary of Ardelyx, Inc.'s Q1 2026 earnings call